Tagged with AI

Taiwan Dr. Tzu-Ling (Karen) Tseng, CEO of Bio Preventive Medicine Corporation in Taiwan, discusses the innovative technology of its patented biomarkers, the success of DNlite and company’s strategy to grow through partnerships with global pharmaceutical companies. What was your vision when you founded Bio Preventive Medicine Corporation (BPM) in 2014? Can…

Taiwan C.Y. Cheng, chairman and president of Formosa Laboratories, shares exciting news about the establishment of a new drug development company, Formosa Pharmaceuticals. He explains how the know-how gained from running a successful international API production business will help Formosa avoid the typical mistakes that young R&D companies face. Mr. Cheng,…

Taiwan With 7,000 employees in 25 locations across 12 countries in the region, PAREXEL now has more than a third of its global staff in Asia Pacific (APAC). Albert Liou, Vice Chairman, Asia Pacific, PAREXEL, discusses the biotech momentum that has been boosting the attractiveness of the region in terms of…

Taiwan Chih-Yi Weng, chairlady and CEO of Charsire Biotechnology, one of Taiwan’s leading biotech companies focused on the development of botanical new drugs as well as topical and personal care products, provides insights into the company’s unique business model and its promising and maturing R&D pipeline, while Charsire was ranked in…

Taiwan Peter Tsai, founder, CEO, and chairman of Orient EuroPharma (OEP), one of the leading groups of healthcare companies in Taiwan, provides insights into his strategic vision to double the group’s revenues within the next five years and nurture the long-term growth of the company he founded in 1982, while OEP’s…

Taiwan Peter Tsai, founder, CEO, and chairman of Orient EuroPharma (OEP), one of the leading groups of healthcare companies in Taiwan, provides insights into his strategic vision to double the group’s revenues within the next five years and nurture the long-term growth of the company he founded in 1982, while OEP’s…

Taiwan Lee Po-Chang, director general of Taiwan’s National Health Insurance Administration (NHIA) details his main priorities to further strengthen the country’s widely acclaimed single-payer health system, which already stands as one of the most advanced in the region, while adapting the NHIA to evolving healthcare needs and to the growing challenges…

Taiwan In an exclusive interview, Amy Huang, general manager of OBI Pharma, shares her plans to bolster the international development of the company and further strengthen its expertise throughout the drug development process. She also elaborates on the key next steps that lie ahead for OBI Pharma’s flagship immuno-oncology therapy, Adagloxad…

Taiwan Wu Tsung-Tsong, Minister Without Portfolio of the Republic of China (Taiwan) supervises and coordinates Taiwan’s Biomedical Industry Innovation Program. In this exclusive interview, he documents his main priorities and the government’s unrivalled commitment to further enhancing the attractiveness of Taiwan’s biotech ecosystem and bolstering a win-win relationship between Taiwan, the…

Taiwan Leveraging Taiwan’s remarkable talent pool in chemistry, some of the country’s fastest-growing companies have been concentrating their efforts on technology platforms that allow them to develop a plethora of potentially game-changing products, rather than focusing all their resources on the risky development of a single, potentially groundbreaking product.   Taiwan…

Taiwan Johnsee Lee, a leading figure in the Taiwanese biotech and pharmaceutical sectors and Chairman of Taiwan Bio Industry Organization, the largest and one of the most influential biotechnology associations in Taiwan, shares his vision for the future development of Taiwan’s thriving biotech sector and the critical success factors he envisions…

Taiwan Founded in 2012, Senhwa Biosciences is mainly engaged in the development and clinical study of small molecule drugs to treat various types of cancer, and its drug development pipelines include CX-5461, a first-in-class drug using G-quadruplex (G4) stabilizer as a mechanism as well as the casein kinase 2 (CK2) inhibitor…